Ask AI
ProCE Banner Activity

Managing BRAF V600E–Mutant mCRC and mNSCLC: Testing and Treatment Considerations for Community Practitioners

PDF

Download this brief resource with clinical pearls related to testing and targeted treatment for BRAF V600E–mutant mCRC and mNSCLC. 

Released: May 07, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Target Audience

This activity is intended for oncologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in the care and treatment of patients with mCRC and/or mNSCLC in community practices.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply the latest evidence and guideline recommendations for the first-line treatment of patients with BRAF V600E-mutant mCRC and mNSCLC

  • Integrate biomarker testing workflows to improve identification and timely treatment selection for patients with BRAF V600E-mutant mCRC and mNSCLC

  • Implement practical strategies to manage adverse events associated with BRAF-targeted combination therapies through appropriate dose modifications and supportive care

  • Collaborate across multidisciplinary care teams to personalize treatment plans and ensure optimal outcomes for patients with BRAF-mutant mCRC and mNSCLC

Disclosure

Primary Author

Christopher Lieu, MD, FASCO: researcher (paid to institution): Genentech, Janssen; consultant/advisor/speaker: Pfizer.

Gregory J. Riely, MD, PhD: investigator: Amgen; research funding: Lilly; researcher: Pfizer.